Loading...
Health outcomes as well as quality of life in young breast cancer survivors are often compromised by chemotherapy-induced loss of ovarian function. Because strategies to preserve fertility including oocyte and embryo cryopreservation are not always possible or acceptable, studies have focused on the effects of luteinizing hormone-releasing hormone analogues in suppressing oocyte development to help preserve future ovarian function. Now, researchers present long-term outcomes of an Italian multicenter, randomized, open-label superiority trial of the luteinizing hormone-releasing hormone (LHRH) analogue triptorelin (3.75 mg intramuscularly 1 week before chemotherapy, then every 4 weeks during chemotherapy) in 281 premenopausal women (median a…